JAZZ PHARMACEUTICALS PLC news, videos and press releases
For more news please use our advanced search feature.
JAZZ PHARMACEUTICALS PLC - More news...
JAZZ PHARMACEUTICALS PLC - More news...
- Jazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024
- Jazz Pharmaceuticals Employees Wear Purple To Support Epilepsy Awareness and Community
- Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
- Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024
- Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting
- Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
- Cancer and the Combination Approach
- Jazz Pharmaceuticals Celebrates International Women’s Day
- Exploring How Jazz Pharmaceuticals Honored U.S. Black History Month
- Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
- Jazz Pharmaceuticals to Host Virtual Zanidatamab R&D Day on Tuesday, March 19, 2024
- Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
- Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2023 Financial Results and Provides 2024 Financial Guidance
- Jazz Pharmaceuticals Appoints Patrick Kennedy to its Board of Directors
- Jazz Pharmaceuticals Appoints Philip Johnson as Chief Financial Officer
- Jazz Pharmaceuticals to Participate in Upcoming March Investor Conferences
- Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024
- Jazz Pharmaceuticals to Report 2023 Full Year and Fourth Quarter Financial Results on February 28, 2024
- Listen to How "Jazz Remix" Fosters a Positive Employee Experience at Jazz Pharmaceuticals
- How This CEO Built a Top 50 Pharma Company Focusing on Culture Day 1
- Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program
- Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program
- Jazz Pharmaceuticals Provides Update on Phase 2 Trial of Investigational JZP150 in Adult Patients with Post-Traumatic Stress Disorder
- Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jazz Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Jazz Pharmaceuticals Presents Updated Phase 2a Data at SABCS 2023 Showcasing Potential of Zanidatamab in HER2+/HR+ Metastatic Breast Cancer
- Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report: Serving our Global Communities
- Jazz Pharmaceuticals to Present Long-Term and Real-World Data Emphasizing Commitment to Treatment-Resistant Epilepsy at the 2023 American Epilepsy Society Annual Meeting
- Jazz Pharmaceuticals to Present New Data Highlighting Advancements in Solid Tumors and Rare Blood Cancers at Upcoming Oncology Meetings
- Jazz Pharmaceuticals' 2022 Corporate Sustainability and Social Impact Report: Using Natural Resources Responsibly